Novel antibody-antibiotic conjugate eliminates intracellular S. aureus

Nature

Volumn 527, Issue 7578, 2015, Pages 323-328

  Lehar, Sophie M ^a   Pillow, Thomas ^a   Xu, Min ^a   Staben, Leanna ^a   Kajihara, Kimberly K ^a   Vandlen, Richard ^a   DePalatis, Laura ^a   Raab, Helga ^a   Hazenbos, Wouter L ^a   Hiroshi Morisaki, J ^a   Kim, Janice ^a   Park, Summer ^a   Darwish, Martine ^a   Lee, Byoung Chul ^a   Hernandez, Hilda ^a   Loyet, Kelly M ^a   Lupardus, Patrick ^a   Fong, Rina ^a   Yan, Donghong ^a   Chalouni, Cecile ^a   Luis, Elizabeth ^a   Khalfin, Yana ^a   Plise, Emile ^a   Cheong, Jonathan ^a   Lyssikatos, Joseph P ^a   Strandh, Magnus ^b   Koefoed, Klaus ^b   Andersen, Peter S ^b   Flygare, John A ^a   Wah Tan, Man ^a   Brown, Eric J ^a   Mariathasan, Sanjeev ^a   more..

^a GENENTECH INC   (United States)

^b Symphogen AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; BACTERIUM ANTIBODY; DAPTOMYCIN; FORMIC ACID; IMMUNOGLOBULIN; LINEZOLID; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS ANTIBODY; POLYMER; RIFALOGUE; RIFAMPICIN DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN; WALL TEICHOIC ACID; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTICS; ANTIBODY; BACTERIUM; CELLS AND CELL COMPONENTS; COLONIZATION; PATHOGEN; RODENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHAGOLYSOSOME; PRIORITY JOURNAL; SINGLE DRUG DOSE; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; ANIMAL; BACTEREMIA; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; HETEROZYGOTE; INTRACELLULAR SPACE; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; PHAGOSOME; STAPHYLOCOCCAL INFECTIONS;

MUS; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; CARRIER STATE; DRUG DESIGN; FEMALE; IMMUNOCONJUGATES; INTRACELLULAR SPACE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICROBIAL SENSITIVITY TESTS; PHAGOSOMES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 84947751820     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature16057     Document Type: Article

References (45)

1. Diekema, D. J. et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32 (suppl. 2), S114-S132 (2001).
2. Lowy, F. D. Staphylococcus aureus infections. N. Engl. J. Med. 339, 520-532 (1998).
3. Boucher, H. W. et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-12 (2009).
4. Nannini, E., Murray, B. E. & Arias, C. A. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus. Curr. Opin. Pharmacol. 10, 516-521 (2010).
5. Thwaites, G. E. & Gant, V. Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus? Nature Rev. Microbiol. 9, 215-222 (2011).
6. Rogers, D. E. & Tompsett, R. The survival of staphylococci within human leukocytes. J. Exp. Med. 95, 209-230 (1952).
7. Gresham, H. D. et al. Survival of Staphylococcus aureus inside neutrophils contributes to infection. J. Immunol. 164, 3713-3722 (2000).
8. Kapral, F. A. & Shayegani, M. G. Intracellular survival of staphylococci. J. Exp. Med. 110, 123-138 (1959).
9. Anwar, S., Prince, L. R., Foster, S. J., Whyte, M. K. & Sabroe, I. The rise and rise of Staphylococcus aureus: laughing in the face of granulocytes. Clin. Exp. Immunol. 157, 216-224 (2009).
10. Fraunholz, M. & Sinha, B. Intracellular Staphylococcus aureus: live-in and let die. Front. Cell. Infect. Microbiol. 2, 43 (2012).
11. Garzoni, C. & Kelley, W. L. Return of the Trojan horse: intracellular phenotype switching and immune evasion by Staphylococcus aureus. EMBO Mol. Med. 3, 115-117 (2011).
12. Rogers, D. E. Studies on bacteriemia. I. Mechanisms relating to the persistence of bacteriemia in rabbits following the intravenous injection of staphylococci. J. Exp. Med. 103, 713-742 (1956).
13. Velasco, E. et al. Comparative study of clinical characteristics of neutropenic and non-neutropenic adult cancer patients with bloodstream infections. Eur. J. Clin. Microbiol. Infect. Dis. 25, 1-7 (2006).
14. Venditti, M. et al. Staphylococcus aureus bacteremia in patients with hematologic malignancies: a retrospective case-control study. Haematologica 88, 923-930 (2003).
15. Bosse, M. J., Gruber, H. E. & Ramp, W. K. Internalization of bacteria by osteoblasts in a patient with recurrent, long-term osteomyelitis. A case report. J. Bone Joint Surg. Am. 87, 1343-1347 (2005).
16. Clement, S. et al. Evidence of an intracellular reservoir in the nasal mucosa of patients with recurrent Staphylococcus aureus rhinosinusitis. J. Infect. Dis. 192, 1023-1028 (2005).
17. Jarry, T. M., Memmi, G. & Cheung, A. L. The expression of α-haemolysin is required for Staphylococcus aureus phagosomal escape after internalization in CFT-1 cells. Cell. Microbiol. 10, 1801-1814 (2008).
18. Que, Y. A. et al. Fibrinogen and fibronectin binding cooperate for valve infection and invasion in Staphylococcus aureus experimental endocarditis. J. Exp. Med. 201, 1627-1635 (2005).
19. Greenlee-Wacker, M. C. et al. Phagocytosis of Staphylococcus aureus by human neutrophils prevents macrophage efferocytosis and induces programmed necrosis. J. Immunol. 192, 4709-4717 (2014).
20. Kobayashi, S. D. et al. Rapid neutrophil destruction following phagocytosis of Staphylococcus aureus. J. Innate Immun. 2, 560-575 (2010).
21. Barcia-Macay, M., Seral, C., Mingeot-Leclercq, M. P., Tulkens, P. M. & Van Bambeke, F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob. Agents Chemother. 50, 841-851 (2006).
22. Sandberg, A., Hessler, J. H., Skov, R. L., Blom, J. & Frimodt-Møller, N. Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. Antimicrob. Agents Chemother. 53, 1874-1883 (2009).
23. Dubowchik, G. M. et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug. Chem. 13, 855-869 (2002).
24. Winstel, V., Xia, G. & Peschel, A. Pathways and roles of wall teichoic acid glycosylation in Staphylococcus aureus. Int. J. Med. Microbiol. 304, 215-221 (2014).
25. Campbell, E. A. et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104, 901-912 (2001).
26. Conlon, B. P. et al. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 503, 365-370 (2013).
27. Fischer, R., Hufnagel, H. & Brock, R. A doubly labeled penetratin analogue as a ratiometric sensor for intracellular proteolytic stability. Bioconjug. Chem. 21, 64-73 (2010).
28. Nielsen, S. L. & Black, F. T. Extracellular and intracellular killing in neutrophil granulocytes of Staphylococcus aureus with rifampicin in combination with dicloxacillin or fusidic acid. J. Antimicrob. Chemother. 43, 407-410 (1999).
29. Kullar, R., Davis, S. L., Levine, D. P. & Rybak, M. J. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin. Infect. Dis. 52, 975-981 (2011).
30. Fowler, V. G. Jr et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355, 653-665 (2006).
31. Yoon, Y. K., Kim, J. Y., Park, D. W., Sohn, J. W. & Kim, M. J. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J. Antimicrob. Chemother. 65, 1015-1018 (2010).
32. Johnson, L. B., Almoujahed, M. O., Ilg, K., Maolood, L. & Khatib, R. Staphylococcus aureus bacteremia: compliance with standard treatment, long-term outcome and predictors of relapse. Scand. J. Infect. Dis. 35, 782-789 (2003).
33. Levin, B. R. Noninherited resistance to antibiotics. Science 305, 1578-1579 (2004).
34. Grant, S. S., Kaufmann, B. B., Chand, N. S., Haseley, N. & Hung, D. T. Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. Proc. Natl Acad. Sci. USA 109, 12147-12152 (2012).
35. Lewis, K. Persister cells. Annu. Rev. Microbiol. 64, 357-372 (2010).
36. Kaiser, P. et al. Cecum lymph node dendritic cells harbor slow-growing bacteria phenotypically tolerant to antibiotic treatment. PLoS Biol. 12, e1001793 (2014).
37. Bryskier, A. Anti-MRSA agents: under investigation, in the exploratory phase and clinically available. Expert Rev. Anti Infect. Ther. 3, 505-553 (2005).
38. Hazenbos, W. L. et al. Novel staphylococcal glycosyltransferases SdgA and SdgB mediate immunogenicity and protection of virulence-associated cell wall proteins. PLoS Pathog. 9, e1003653 (2013).
39. Monk, I. R., Shah, I. M., Xu, M., Tan, M. W. & Foster, T. J. Transforming the untransformable: application of direct transformation to manipulate genetically Staphylococcus aureus and Staphylococcus epidermidis. MBio 3, e00277-11 (2012).
40. Meijer, P. J. et al. Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. J. Mol. Biol. 358, 764-772 (2006).
41. Meijer, P. J., Nielsen, L. S., Lantto, J. & Jensen, A. Human antibody repertoires. Methods Mol. Biol. 525, 261-277 (2009).
42. Van Duzer, J. et al. Rifamycin Analogs and Uses Thereof (Activbiotics, 2005).
43. Junutula, J. R. et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nature Biotechnol. 26, 925-932 (2008).
44. Boullanger, P., Descotes, G., Flandrois, J. P. & Marmet, D. Synthesis of 4-O-(2-acetamido-2-deoxy-β-d-glucopyranosyl)-d-ribitol, antigenic determinant of Staphylococcus aureus. Carbohydr. Res. 110, 153-158 (1982).
45. Vaudaux, P. & Waldvogel, F. A. Gentamicin antibacterial activity in the presence of human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 16, 743-749 (1979).